181 results on '"Cao, Xiting"'
Search Results
2. Cardiovascular death risk in patients with solid tumors: a population-based study in the United States.
3. Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma
4. Use of novel cancer staging model to analyze healthcare costs of commercially insured patients with colorectal cancer.
5. Associations between physical activity and all-cause and cardiovascular mortality in adults with type 2 diabetes mellitus: A prospective cohort study from NHANES 2007–2018
6. MDS-447 A Systematic Literature Review of the Economic Burden in Patients With Myelodysplastic Syndromes
7. MDS-442 A Systematic Literature Review of the Clinical Burden in Patients With Myelodysplastic Syndromes
8. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non–Small-Cell Lung Cancer
9. Survival Rates and Health Care Costs for Patients With Advanced Bladder Cancer Treated and Untreated With Chemotherapy
10. Treatment Patterns for Advanced Non–Small-cell Lung Cancer After Platinum-containing Therapy in U.S. Community Oncology Clinical Practice
11. Approaches for Patient Recruitment Modeling and Simulation
12. Treatment patterns, resource utilization and clinical outcomes in patients with higher risk myelodysplastic syndromes (MDS) in United States community practices.
13. Systematic Literature Review and Meta-analysis of Medication Adherence With Once-weekly Versus Once-daily Therapy
14. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom
15. Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores
16. Poster: MDS-442 A Systematic Literature Review of the Clinical Burden in Patients With Myelodysplastic Syndromes
17. Poster: MDS-447 A Systematic Literature Review of the Economic Burden in Patients With Myelodysplastic Syndromes
18. Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study
19. Prognostic characteristics of immune subtypes associated with acute myeloid leukemia and their identification in cell subsets based on single-cell sequencing analysis
20. Comprehensive Analysis of N6-Methyladenosine-Related Long Noncoding RNA Prognosis of Acute Myeloid Leukemia and Immune Cell Infiltration
21. Mogroside V Improves Follicular Development and Ovulation in Young-Adult PCOS Rats Induced by Letrozole and High-Fat Diet Through Promoting Glycolysis
22. Clinical Characteristics and Late-Line Treatment Patterns of Patients with Chronic Myeloid Leukemia Who Received 2 Prior Lines of Tyrosine Kinase Inhibitor Therapy in US Community Oncology Practices
23. Better Medications Adherence Lowers Cardiovascular Events, Stroke, and All-Cause Mortality Risk: A Dose-Response Meta-Analysis
24. Resveratrol Improves Follicular Development of PCOS Rats by Regulating the Glycolytic Pathway
25. Approaches for Patient Recruitment Modeling and Simulation
26. Poster: MDS-370: Treatments and Outcomes for Patients with Myelodysplastic Syndromes (MDS) by Revised International Prognostic Scoring System (IPSS-R) Scores at the Huntsman Cancer Institute (HCI)
27. MDS-370: Treatments and Outcomes for Patients with Myelodysplastic Syndromes (MDS) by Revised International Prognostic Scoring System (IPSS-R) Scores at the Huntsman Cancer Institute (HCI)
28. Treatments and outcomes for patients with myelodysplastic syndrome (MDS) by Revised International Prognostic Scoring System (IPSS-R) scores at the Huntsman Cancer Institute (HCI).
29. Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates
30. Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis
31. Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis
32. Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP)
33. MDS-112: A SEER-Medicare Analysis of Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agent
34. CML-085: Discontinuation of Tyrosine Kinase Inhibitor (TKI) Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in US Clinical Practice Following Updates to NCCN CML Practice Guidelines
35. MDS-108: Healthcare Resource Utilization and Costs in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis
36. Discontinuation of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia in chronic phase (CML-CP) in US clinical practice after guideline updates.
37. Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis
38. Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline Updates
39. Real-world clinical outcomes of pazopanib immediately following immunotherapy discontinuation for the treatment of advanced renal cell carcinoma.
40. Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices
41. Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States
42. Treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory Hodgkin lymphoma treated with brentuximab vedotin
43. Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study
44. Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan
45. Genome-wide association studies identify genetic loci for low von Willebrand factor levels : Corrigendum
46. Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan
47. Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting
48. P1.06-021 Treatment Patterns and Healthcare Resource Use from a Retrospective Cohort of Japanese Patients with Advanced Non-Small Cell Lung Cancer
49. Treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory Hodgkin lymphoma treated with brentuximab vedotin.
50. Genome-wide association studies identify genetic loci for low von Willebrand factor levels
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.